ESR1 and breast carcinoma: It is important to note that estrogen represses SCD-1 in metabolic tissues but activates it in ER+ breast cancer cells, and that activation of SCD-1 via SREBP1 is central to estrogen-induced proliferation, thereby positioning the SREBP1–SCD1 axis as a therapeutic target for ER+ breast cancer [67,68].